

KIDANI CAPITAL PARTNERS INC.
804-750 West Pender Street
Vancouver, BC V6C 2T7

1040426 BC LTD.
804-750 West Pender Street
Vancouver, BC V6C 2T7

1040428 BC LTD.
804-750 West Pender Street
Vancouver, BC V6C 2T7

1040433 BC LTD.
804-750 West Pender Street
Vancouver, BC V6C 2T7

1040436 BC LTD.
804-750 West Pender Street
Vancouver, BC V6C 2T7

1040440 BC LTD.
804-750 West Pender Street
Vancouver, BC V6C 2T7

Genix Pharmaceuticals Corp.
(formerly 1040442 BC LTD.)
804-750 West Pender Street
Vancouver, BC V6C 2T7

Kidani Capital Announces Closing of Plan of Arrangement with 1040426 B.C. Ltd., 1040428 B.C. Ltd., 1040433 B.C. Ltd., 1040436 B.C. Ltd., 1040440 BC Ltd. and 1040442 BC Ltd.

Vancouver, BC / October 29, 2015 – Kidani Capital Partners Inc. (“**Kidani**”), 1040426 BC Ltd. (“**1040426**”), 1040428 B.C. Ltd. (“**1040428**”), 1040433 BC Ltd. (“**1040433**”), 1040436 BC Ltd. (“**1040436**”), 1040440 BC Ltd. (“**1040440**”) and Genix Pharmaceuticals Corp. (formerly 1040442 BC Ltd.) (“**Genix**”) are pleased to announce that on October 29, 2015 (the “**Effective Date**”), they completed a statutory arrangement under a plan of arrangement (the “**Arrangement**”). As a result of completing the Arrangement, 1040426, 1040428, 1040433, 1040436, 1040440 and Genix became reporting issuers in the provinces of British Columbia and Alberta.

Completion of the Arrangement as set forth in the arrangement agreement and plan of arrangement dated July 20, 2015 (the “**Arrangement Agreement**”) among Kidani, 1040426, 1040428, 1040433, 1040436, 1040440 and 1040442 B.C. Ltd. was approved by the shareholders of Kidani on August 14, 2015 and by a Final Order granted by the Supreme Court of British Columbia on August 19, 2015 in accordance with Part 9 of the Business Corporations Act (British Columbia).

1040426 BC Ltd.:

Under the terms of the Arrangement Agreement and on the Effective Date, 1040426 issued a total of 396,600 common shares to the shareholders of Kidani at a deemed price of \$0.01 per common share.

The CUSIP number for the common shares of 1040426 is 68247A107.

As of the Effective Date, the board of directors of 1040426 are Christopher P. Cherry, Robert M. Dzisiak and Stephen Brohman and the sole officer is Christopher P. Cherry as President, CEO and CFO.

1040428 BC Ltd.:

Under the terms of the Arrangement Agreement and on the Effective Date, 1040428 issued a total of 396,600 common shares to the shareholders of Kidani at a deemed price of \$0.01 per common share.

The CUSIP number for the common shares of 1040428 is 68247B105.

As of the Effective Date, the board of directors of 1040428 are Christopher P. Cherry, Robert M. Dzisiak and Stephen Brohman and the sole officer is Christopher P. Cherry as President, CEO and CFO.

1040433 BC Ltd.:

Under the terms of the Arrangement Agreement and on the Effective Date, 1040433 issued a total of 396,600 common shares to the shareholders of Kidani at a deemed price of \$0.01 per common share.

The CUSIP number for the common shares of 1040433 is 68247C103.

As of the Effective Date, the board of directors of 1040433 are Christopher P. Cherry, Robert M. Dzisiak and Stephen Brohman and the sole officer is Christopher P. Cherry as President, CEO and CFO.

1040436 BC Ltd.:

Under the terms of the Arrangement Agreement and on the Effective Date, 1040436 issued a total of 396,600 common shares to the shareholders of Kidani at a deemed price of \$0.01 per common share.

The CUSIP number for the common shares of 1040433 is 68247D101.

As of the Effective Date, the board of directors of 1040436 are Robert M. Riley, Jonathan Samuda and Andrew Mugridge and the sole officer is Robert M. Riley as CEO and CFO.

1040440 BC Ltd.:

Under the terms of the Arrangement Agreement and on the Effective Date, 1040440 issued a total of 396,600 common shares to the shareholders of Kidani at a deemed price of \$0.01 per common share.

The CUSIP number for the common shares of 1040440 is 6824E109.

As of the Effective Date, the board of directors of 1040440 are Christopher P. Cherry, Robert M. Dzisiak and Stephen Brohman and the sole officer is Christopher P. Cherry as President, CEO and CFO.

Genix Pharmaceuticals Corp.:

Under the terms of the Arrangement Agreement and on the Effective Date, Genix issued a total of 396,600 common shares to the shareholders of Kidani at a deemed price of \$0.01 per common share.

The CUSIP number for the common shares of Genix is 37231L106.

As of the Effective Date, the board of directors of Genix are Christopher P. Cherry, Robert M. Dzisiak and Stephen Brohman and the sole officer is Christopher P. Cherry as President, CEO and CFO.

About Kidani Capital Partners Inc.:

Kidani is a business development services company. It provides business development services to new and emerging businesses, including making introductions to accountants, lawyers, brokers, transfer agents, and various other professionals and service providers to assist companies in raising capital and going public. It also advises companies on corporate structure and in business development, including finding and advising on opportunities in mergers and acquisitions.

For further information regarding each of Kidani, 1040426, 1040428, 1040433, 1040440 and Genix please contact:

Christopher P. Cherry
President, CEO & CFO
T: 604.908.3095
E: chris@cherryconsulting.ca

For further information regarding 1040436 BC Ltd. please contact:

Robert M. Riley
CEO & CFO
T: 604.889.4302
E: robriley@telus.net

Cautionary Note Regarding Forward-Looking Information

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements herein relating to analyses and other information that are based on anticipated events, forecasts of future results, estimates of amounts not yet determinable and assumptions of

management, including the anticipated completion of the Arrangement and the benefits of such transaction and related transactions to Kidani, 1040426, 1040428, 1040433, 1040436, 1040440, Genix and Kidani's shareholders. Forward-looking statements can be identified by the use of words such as "intends", "plans", "expects" or "does not expect", "is expected", "scheduled", "estimates", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the possibility that shareholders will not approve the Arrangement as currently proposed or at all; that even if approved the Kidani may for one or more reasons determine not to proceed with the Arrangement; that the transactions contemplated by one or more (or all) of the letters of intent with each Target Kidani will never complete or, if completed, will never result in a profitable business; and other factors discussed under "Risk Factors" in the Kidani's management information circular to be mailed to all shareholders in connection with the Meeting. Although the Kidani has attempted to identify material factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained in this press release are made as of the date of this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Kidani will update forward-looking statements as required.